VivoSeq
Hematology

Polycythemia Vera

41

Pipeline Programs↗

16

Active Trials↗

25

Companies Involved↗

Polycythemia Vera is a moderately active landscape with 41 programs across 25 companies. The most active players are AstraZeneca, TG Therapeutics, Inc., Roche. 5 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

27/100

Mech. Concentration

7/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1T

TG Therapeutics, Inc.

1 program

Phase 1Roche logo

Roche

1 program

Phase 2K

Kartos Therapeutics, Inc.

1 program

Phase 2S

Silence Therapeutics plc

1 program

Phase 2K

Kura Oncology, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

35 of 42 classified programs — the dominant modality here.

17%ALL OTHERSProtein / enzyme25%Peptide25%Monoclonal antibody12%RNA therapy12%Gene therapy12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 98% of 46 pipeline programs.

Analysis

Trial Status

49

clinical trials

Completed21 · 43%
Recruiting9 · 18%
Terminated6 · 12%
Unknown status4 · 8%
Not yet recruiting4 · 8%
Active, not recruiting3 · 6%
Other2 · 4%

Clinical Trials

Trial Activity

49 trials

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Recruiting·Italfarmaco logoItalfarmaco·Phase 3·NCT06093672·220 enrolled
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Recruiting·MMassachusetts General Hospital·Phase 2·NCT04644211·60 enrolled
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Recruiting·CChengdu Zenitar Biomedical Technology Co., Ltd·Phase 2·NCT07232290·60 enrolled
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Recruiting·DDisc Medicine, Inc·Phase 2·NCT06985147·60 enrolled
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Recruiting·UUniversity of Birmingham·Phase 3·NCT04116502·586 enrolled
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 1·NCT06752746·108 enrolled
Unmasking Polycythemia Vera in Long-Standing Essential Thrombocythemia: A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Recruiting·FFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS·N/A·NCT07203768·678 enrolled
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Recruiting·FFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS·N/A·NCT06506084·429 enrolled
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
Recruiting·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 3·NCT07429266·250 enrolled
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
Active, not recruiting·Protagonist Therapeutics logoProtagonist Therapeutics·Phase 3·NCT05210790·293 enrolled
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Active, not recruiting·Protagonist Therapeutics logoProtagonist Therapeutics·Phase 3·NCT06033586·46 enrolled
Study to Assess SLN124 in Patients With Polycythemia Vera
Active, not recruiting·SSilence Therapeutics plc·Phase 1/2·NCT05499013·69 enrolled
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Not yet recruiting·PPharmaEssentia·Phase 4·NCT06290765·70 enrolled
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
Not yet recruiting·BBeBetter Med Inc·Phase 1·NCT07012109·90 enrolled
Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study
Not yet recruiting·FFederico II University·N/A·NCT07282132·150 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)